Cellavision Ab · OMXSTO:CEVI
Cellavision Ab — Shareholder Meeting (April 2009)
19 slides from Cellavision Ab's shareholder meeting presentation, Apr 27, 2009
Slide 1: CellaVision Annual General Meeting
CellaVision Annual General Meeting Lund April 27 2009
Slide 2: CellaVision is world leader in a market with large potential
CellaVision is world leader in a market with large potential, offering Automated Digital Cell Morphology
Slide 3: CellaVision in short
CellaVision in short ― We offer automated digital cell morphology within hematology ― Sales through exclusive and non-exclusive distributors. Direct sales through subsidiaries in the Nordic countries, US (in parallell with Sysmex), Canada and Japan. ― Headquarters in Lund, Sweden. ― Net Sales in 200
Slide 4: Global Customer Base
Global Customer Base ― More than 500 systems mainly in Europe and the U.S. ― Hospital and commercial hematology laboratories ― All customers have automatic blood cell counters for routine analysis ― Need for automation of manual cell differentials ― The operator is a biomedical scientist
Slide 5: The hematology analysis market comprises more than 1 billion CBC tests a year
The hematology analysis market comprises more than 1 billion CBC tests a year—manual differential work equivalent to more than USD 1 billion
Slide 6: Market for CellaVision products about 15 000 laboratories
The company estimates the market for CellaVision products to include about 15 000 laboratories worldwide. The market value is estimated to minimum SEK 5 billion In a mature market the products will be replaced in a 3-5 years cycle ―
Slide 7: Our Unique Technology Adds Value
Our Unique Technology Adds Value ― Efficiency; cost reduction and increased productivity ― Proficiency; increased quality of results ― Connectivity between sites; enhanced opportunity for collaboration and sharing of competences.
Slide 8: CellaVision's Offering
CellaVision’s Offering Analysis instruments ― CellaVision™ DM96 ― CellaVision™ DM8 Software ― CellaVision™ Remote Review (for DM96/DM8) ― CellaVision™Body Fluid Software, Software for education/competency testing ― CellaVision™ Competency Software Accessories Service
Slide 9: Geographical presence
Geographical precense More than 500 systems
Slide 10: Owner Structure
Owner Structure Shareholder # shares % H & B Capital LP 4 073 139 17,1 Stiftelsen Industrifonden 3 587 25 15,0 Metallica Förvaltnings AB 2 738 967 11,5 Christer Fåhraeus m bolag 2 400 000 10,1 Life Equity Sweden KB 1 606 783 6,7 Unionen 1 090 000 4,6 Others 8 355 401 35,0 TOTAL 23 851 547 100,0
Slide 11: Styrelse
Styrelse Lars Gatenbeck, Ordförande • Christer Fåhraeus Niels P. Freiesleben • Torbjörn Kronander • Sven-Åke Henningsson
Slide 12: CellaVision 2008
CellaVision 2008 e CELLAVISION G
Slide 13: Important achievements in 2008
Important achievements in 2008 ― Net sales increased by 35 % to SEK 100 million ― Profit before income tax increased to SEK 13 million ― 6 consecutive quarters report positive result ― Continued strong sales on the European market and an increase in North America. ― Establishment of own sales organi
Slide 14: Net Sales, EBIT and FTEs 2001-2008
Net Sales, EBIT and FTEs 2001-2008
Slide 15: Net sales by geographical market
Net sales by geographical market 2008 2007
Slide 16: Q1 2009
Q1 2009 Continued strong sales trend during Q1 2009 ― Net sales for the quarter rose by 19 % to SEK 22.0 million (18.5). ― The operating profit for the period was SEK 0.9 million (1.3). ― Earnings per share for the period amounted to SEK 0.02 (0.05). ― Cash and cash equivalents amounted to SEK 14.5
Slide 17: Q1 2009 cont'd
Q1 2009 cont’d Important events after the reporting period ― The Japanese subsidiary received its first order. ― David Autry was appointed President of CellaVision North America. ― CellaVision was nominated for the SwedenBIO Award for its successes during 2008.
Slide 18: CellaVision Going Forward
CellaVision Going Forward Hematology Business ― Continue sales growth ― Continue global market penetration ― Hardware cost reduction to extend market ― Refine business model to more recurrent revenue ― Software development, other applications like bone marrow Other Business Opportunities ― New marke
Slide 19: For more information, please visit www.cellavision.com
For more information, please visit www.cellavision.com CellaVision was placed on NASDAQ OMX First North Premier on the 16th of February.